NGNE

Company Overview — What Does Neurogene Inc. Do?

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neurogene Inc. (NGNE) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jonathan G. Drachman and employs approximately 90 people, headquartered in SEATTLE, New York. With a market capitalization of $337M, NGNE is one of the notable companies in the Healthcare sector.

Neurogene Inc. (NGNE) Stock Rating — Reduce (April 2026)

As of April 2026, Neurogene Inc. receives a Reduce rating with a composite score of 26.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NGNE ranks #3,528 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Neurogene Inc. ranks #554 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NGNE Stock Price and 52-Week Range

Neurogene Inc. (NGNE) currently trades at $20.38. The stock lost $0.99 (4.6%) in the most recent trading session. The 52-week high for NGNE is $37.27, which means the stock is currently trading -45.3% from its annual peak. The 52-week low is $6.88, putting the stock 196.4% above its annual trough. Recent trading volume was 120K shares, suggesting relatively thin trading activity.

Is NGNE Overvalued or Undervalued? — Valuation Analysis

Neurogene Inc. (NGNE) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.23x, versus the sector average of 2.75x.

At current multiples, Neurogene Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Neurogene Inc. Profitability — ROE, Margins, and Quality Score

Neurogene Inc. (NGNE) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -32.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.7% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NGNE Debt, Balance Sheet, and Financial Health

Neurogene Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 16.56x, indicating strong short-term liquidity. Total debt on the balance sheet is $7,000. Cash and equivalents stand at $71M.

NGNE has a beta of 1.93, meaning it is more volatile than the broader market — a $10,000 investment in NGNE would be expected to move 92.6% more than the S&P 500 on any given day. The stability factor score for Neurogene Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Neurogene Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Neurogene Inc. reported revenue of $0 and earnings per share (EPS) of $-4.24. Net income for the quarter was $-86M. Operating income came in at $-98M.

In FY 2025, Neurogene Inc. reported revenue of $0 and earnings per share (EPS) of $-4.24. Net income for the quarter was $-90M. Operating income came in at $-103M.

In Q3 2025, Neurogene Inc. reported revenue of $0 and earnings per share (EPS) of $-0.99. Net income for the quarter was $-21M. Operating income came in at $-24M.

In Q2 2025, Neurogene Inc. reported revenue of $0 and earnings per share (EPS) of $-1.05. Net income for the quarter was $-22M. Operating income came in at $-26M.

Over the past 8 quarters, Neurogene Inc. has experienced revenue contraction from $925,000 to $0. Investors analyzing NGNE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NGNE Dividend Yield and Income Analysis

Neurogene Inc. (NGNE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NGNE Momentum and Technical Analysis Profile

Neurogene Inc. (NGNE) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 1/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NGNE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Neurogene Inc. (NGNE) ranks #554 out of 838 stocks based on the Blank Capital composite score. This places NGNE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NGNE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NGNE vs S&P 500 (SPY) comparison to assess how Neurogene Inc. stacks up against the broader market across all factor dimensions.

NGNE Next Earnings Date

No upcoming earnings date has been announced for Neurogene Inc. (NGNE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NGNE? — Investment Thesis Summary

The quantitative profile for Neurogene Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. High volatility (stability score 21/100) increases portfolio risk.

In summary, Neurogene Inc. (NGNE) earns a Reduce rating with a composite score of 26.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NGNE stock.

Related Resources for NGNE Investors

Explore more research and tools: NGNE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NGNE head-to-head with peers: NGNE vs AZN, NGNE vs SLGL, NGNE vs VMD.